Brokerages Set Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Price Target at $34.33

Shares of Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) have earned a consensus recommendation of “Hold” from the nine analysts that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $34.3333.

A number of equities analysts recently weighed in on the company. Zacks Research raised Lakefront Biotherapeutics American Depositary Shares from a “strong sell” rating to a “hold” rating in a report on Monday, June 8th. Weiss Ratings reissued a “hold (c)” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a report on Tuesday, May 26th. Morgan Stanley assumed coverage on Lakefront Biotherapeutics American Depositary Shares in a research note on Friday, July 10th. They set an “equal weight” rating and a $30.00 target price for the company. Finally, Wall Street Zen cut shares of Lakefront Biotherapeutics American Depositary Shares from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th.

Lakefront Biotherapeutics American Depositary Shares Trading Up 0.7%

Shares of LKFT stock opened at $29.23 on Friday. The stock has a 50 day moving average of $28.71 and a 200 day moving average of $30.69. The stock has a market cap of $1.93 billion, a P/E ratio of -20.73 and a beta of 0.25. Lakefront Biotherapeutics American Depositary Shares has a twelve month low of $26.42 and a twelve month high of $37.78.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $0.25 EPS for the quarter, topping the consensus estimate of ($1.27) by $1.52. The company had revenue of $8.75 million during the quarter, compared to analysts’ expectations of $11.26 million. On average, research analysts predict that Lakefront Biotherapeutics American Depositary Shares will post -10.83 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Lakefront Biotherapeutics American Depositary Shares

Hedge funds and other institutional investors have recently modified their holdings of the business. State of Wyoming acquired a new position in Lakefront Biotherapeutics American Depositary Shares during the 2nd quarter worth about $28,000. Van ECK Associates Corp grew its position in Lakefront Biotherapeutics American Depositary Shares by 61.6% in the 4th quarter. Van ECK Associates Corp now owns 1,968 shares of the biotechnology company’s stock valued at $64,000 after acquiring an additional 750 shares in the last quarter. Arax Advisory Partners grew its holdings in shares of Lakefront Biotherapeutics American Depositary Shares by 319.2% in the fourth quarter. Arax Advisory Partners now owns 2,335 shares of the biotechnology company’s stock valued at $76,000 after purchasing an additional 1,778 shares in the last quarter. Quadrant Capital Group LLC acquired a new position in shares of Lakefront Biotherapeutics American Depositary Shares in the third quarter valued at approximately $134,000. Finally, Squarepoint Ops LLC acquired a new position in shares of Lakefront Biotherapeutics American Depositary Shares in the third quarter valued at approximately $211,000. 32.46% of the stock is owned by hedge funds and other institutional investors.

Lakefront Biotherapeutics American Depositary Shares Company Profile

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.